Objectives: Invasive aspergillosis (IA) caused by Aspergillus terreus is a significant cause of morbidity and mortality in patients with haematological malignancy (HM). Very few data are available in this patient population to differentiate IA patients with A. terreus from those with non-terreus species of Aspergillus to compare outcomes. We retrospectively investigated 513 HM patients who were treated for either definite or probable IA between June 1993 and August 2012 in a cancer centre.
Introduction
The epidemiology of invasive aspergillosis (IA) continues to change in patients with haematological malignancies (HMs). Recently, some centres have observed a decline in the incidence/prevalence of Aspergillus infections. 1 -3 Improvement in the attributable mortality with advances in diagnosis and treatment 4 -7 contrasts with the fact that IA remains a devastating disease with poor prognosis in immunocompromised patients. 5, 6 Historically, Aspergillus fumigatus was the most common species and accounted for the majority of documented cases of IA. 8 -10 Aspergillus terreus that has acquired resistance or is intrinsically resistant to amphotericin B may eventually become more common due to environmental and regional differences. 8,11 -17 Some cancer centres have reported that IA with A. terreus is second or third to A. fumigatus in frequency, with rates of 15% evaluate the outcome and compare the incidence and risk factors associated with IA caused by A. terreus and non-terreus Aspergillus species over 20 years of surveillance.
Patients and methods
Between June 1993 and August 2012, we conducted a retrospective review of the medical records of 513 patients with HM admitted to our institution with a microbiologically documented diagnosis of IA. IA was defined as probable or definite according to the criteria of the European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG). 26 A waiver of informed consent and a waiver of authorization was requested and provided by our institutional review board.
Demographic characteristics and clinical information were recorded for all study patients: gender, age, underlying HM, history of haematopoietic stem cell transplant, presence of graft-versus-host disease (GVHD), duration of neutropenia, persistence of neutropenia during therapy, high-dose steroid use (defined as the equivalent of 600 mg of prednisone), tacrolimus use, immunotherapy during infection including white blood cell transfusion, granulocyte -macrophage colony stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-g (IFN-g), intensive care unit (ICU) stay and need for mechanical ventilation. All vital signs and symptoms were recorded at the beginning of the primary antifungal regimen and at the end of total antifungal therapy. Type and site of either definite or probable IA, along with prior antifungal prophylaxis, breakthrough infection and antifungal therapy, were also recorded. Outcomes were assessed at the end of total antifungal therapy.
Definitions

Definite aspergillosis
IA was considered to be definite if tissue histopathology revealed the presence of septate, acute branching hyphae and if a culture obtained from the same tissue specimen using an invasive procedure, such as transbronchial biopsy or percutaneous needle aspiration, was found to be positive for Aspergillus infection.
Probable aspergillosis
IA was considered to be probable in patients with cancer and recipients of haematopoietic stem cell transplant in the context of neutropenia lasting ≥10 days, GVHD, cytotoxic therapy for malignant or immunological disease or corticosteroid treatment (daily prednisone equivalent ≥10 mg for .3 weeks). In addition, patients with probable aspergillosis had one sputum culture specimen or one bronchoalveolar lavage washing or brushing specimen from which an Aspergillus species had been isolated, as well as new infiltrates on chest CT findings (e.g. halo signs, air crescent signs or cavity within the area of consolidation) that were consistent with the presence of Aspergillus infection.
Neutropenia
Neutropenia was defined by the detection of ,500 neutrophils/mm 3 at the onset of infection.
Breakthrough fungal infection
Breakthrough IA was defined as infection in a patient receiving systemic prophylactic antifungals with known activity against Aspergillus species for at least 7 days before the onset of IA.
Response
Favourable response was defined as either complete or partial resolution of clinical, radiographic and microbiological abnormalities attributable to IA compared with baseline. Radiographic response was defined as .50% improvement from the baseline. This was assessed 4 -6 weeks following the initiation of the therapy.
Unfavourable outcome was defined as either progression or stable infection based on worsening or non-resolution of clinical and radiographic abnormalities and persistently positive cultures, histopathological findings or Aspergillus antigen assays.
Statistical methods
Categorical variables were compared using the x 2 test or Fisher's exact test and continuous variables were compared by Wilcoxon rank-sum tests. A Cochran -Mantel -Haenszel test was performed to adjust for the time effect (period 1993 -2002 versus 2003 -12) when assessing the association between Aspergillus species and the treatment patients received. In addition, multiple logistic regression analysis was used to evaluate the independent effect of infection by A. terreus on the final response. With mortality due to other causes as a competing event, competing risk analysis was performed to evaluate the independent effect of infection by A. terreus on IA-associated mortality. All tests were two-sided with a significance level of 0.05. The statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) and R version 2.15.0 (R Development Core Team, 2008).
Results
Of the 513 patients with HM who were treated for IA at The University of Texas MD Anderson Cancer Center between June 1993 and August 2012, 96 (18.7%) were infected with A. terreus alone and 335 (65.3%) with other Aspergillus species (non-A. terreus), including 143 with Aspergillus fumigatus (27.9%), 112 with Aspergillus flavus (21.9%) and 49 with Aspergillus niger (9.6%). Other non-terreus Aspergillus species identified included Aspergillus nidulans, Aspergillus versicolor and Aspergillus glaucus. Some of the infections with non-terreus Aspergillus species were due to more than one Aspergillus species. The remaining 82 patients had mixed infections with A. terreus along with nonterreus Aspergillus (n ¼ 27) or unidentified Aspergillus species (n¼ 55). These patients were excluded from the analysis.
The two groups of patients (A. terreus versus non-terreus Aspergillus) were compared in their clinical parameters and treatment outcomes. A probable diagnosis of IA was highly represented in both groups (72% of the A. terreus group and 66% of the non-terreus Aspergillus group) while a definite diagnosis of IA was recorded in 28% of the A. terreus group and 34% of the non-terreus Aspergillus group ( Table 1 ). The majority of IA cases were invasive pulmonary infections (88% of the A. terreus group and 81% of the non-terreus Aspergillus group). Other comparable parameters included gender, transplantation status prior to IA, presence of GVHD, neutropenia prior to and at onset of IA, steroid use and tacrolimus use. On the other hand, there were some baseline imbalances between these two groups. Patients from the A. terreus group were significantly younger than those from the non-terreus Aspergillus group (median age 46 versus 54 years, P, 0.001), more likely to be leukaemia patients (85% versus 73%, P ¼ 0.01) and less likely to be lymphoma patients (9% versus 23%, P ¼ 0.003). Although there was no statistical difference in the rate of neutropenia prior to IA, neutropenic patients in the A. terreus group had longer duration of neutropenia than those in the non-terreus Aspergillus group (median days 28 versus 15, P ¼ 0.03). Most symptoms at baseline were comparable between the two groups, such as fever, haemoptysis and Aspergillus terreus versus Aspergillus non-terreus shortness of breath. However, cough was more common in the non-terreus Aspergillus group than in the A. terreus group (62% versus 49%, P ¼ 0.02). Patients in the A. terreus group were more likely to have received prophylactic antifungal therapy than those in the non-terreus Aspergillus group (82% versus 68%, P¼ 0.007) and, among those who received prophylaxis, breakthrough fungal infections occurred more frequently in the A. terreus group (91% versus 77%, P ¼ 0.009). Overall, the regimens for IA treatment had a significantly different distribution between the two groups. The A. terreus group was less likely to be treated with azoles (29% versus 52%, P,0.0001) and echinocandins (32% versus 44%, P ¼ 0.027) compared with the non-terreus Aspergillus group. However, further analysis showed that these differences were due to a time effect. In our study, IA infections with A. terreus occurred more frequently in the early years ( Figure 1 During IA, the A. terreus group was more likely to receive immunotherapy (80% versus 67%, P ¼ 0.018), stay in an ICU (Table 3) . Specifically, patients infected with A. terreus were 1.4 times (95% CI 1.02 -2.0) more likely to have an IA-associated death than patients infected with other Aspergillus species (P¼ 0.038). The difference in IA-associated mortality between these two groups is shown in Figure 2 .
Discussion
This is the largest retrospective study evaluating IA due to A. terreus in comparison with infection with non-terreus Aspergillus species. In this study we demonstrated that IA due to A. terreus displayed a poor clinical outcome and was associated with higher mortality. In addition, A. terreus infection was an independent predictor of treatment failure and mortality from other predictors, such as antifungal therapy. Days after IA diagnosis Probability of IA-associated mortality There are many factors that could have contributed to this poor outcome other than the types of pathogen, including the host factors and the underlying diseases. 19, 27 Prolonged and profound neutropenia for .10 consecutive days with absolute neutrophil cell counts ,500 cells/mL constitutes one of the most common factors predisposing patients to IA. 27 -29 Conforming to the trend seen in a previous limited study done at our institution, 18 we showed in this study that prolonged neutropenia, with a median of 28 days, is statistically associated with a higher prevalence of IA due to A. terreus.
The diagnosis, prevention and management of IA have been changing continuously over the last decade, which explains the epidemiological shifts of IA in HM patients. Despite the shift towards a decrease in incidence 1 -3 and an improvement in mortality, 30 IA remains an overwhelming disease for immunosuppressed patients with HM, 28 especially those infected by intrinsically resistant species, such as A. terreus. Previous studies have shown that patients with A. terreus respond better to antiAspergillus azoles than other antifungal drugs. 21, 23 However, multivariate analysis found that A. terreus is associated with poor prognosis independently of the use of anti-Aspergillus azoles. These features suggest two possibilities that could occur concomitantly: (i) A. terreus may have virulence factors that other species do not have; 31 -38 and (ii) the increase in azole resistance among A. terreus species 17 could also have had some influence on the study results.
Fundamental differences between A. terreus and other Aspergillus species may partly explain their differences in epidemiology, susceptibility to antifungal drugs and outcome of IA. 9,20,31 -36,38,39 In our study, we found that infections with A. terreus were more likely to present in leukaemia patients and had higher rates of breakthrough infections on antifungal prophylaxis. On the other hand, several studies reported that A. fumigatus had predominance in the environment, 13, 39 and lower inocula are necessary for infection with A. fumigatus than A. terreus, 32 which helps to explain the higher prevalence of A. fumigatus over A. terreus infections. 31, 32 A. terreus infection may reflect an endogenous rather than an exogenous origin of infections. 31, 32 It is possible that A. terreus requires a stronger immunosuppressant regimen than A. fumigatus for the development of disease, but does not necessarily require a de novo infection due to its long-term persistence in macrophages. 32, 35 The different strategies detected between A. terreus and non-terreus Aspergillus species to survive the attack of host immune cells 35 add significant information to increase our understanding of the complex interplay between host and fungi in the pathogenesis of IA and species differences in outcome.
Resistance to triazoles in non-terreus Aspergillus species has been recognized for more than two decades, and has been reported recently among A. terreus strains in Denmark. 17, 40 This resistance has been associated with the use of azoles for agricultural and material preservation purposes. 39 Specific mutations in cyp51A may result in resistance to all three triazoles and other resistance mechanisms may be present. 39, 40 However, the epidemiological transition with a tendency for the reemergence of A. terreus IA after 2009 and the association of A. terreus with breakthrough infections and primary antiAspergillus azole prophylaxis in univariate analysis in our study possibly indicate the emergence of Aspergillus species resistant to anti-Aspergillus azoles.
The effects of other variables could also have contributed to the poor outcome. For example, immunotherapy (e.g. granulocyte transfusion) as adjuvant therapy was used to a greater extent in patients with A. terreus infections than in patients with other Aspergillus infections (P ¼ 0.018). Despite the small proportion of cases (26%), the deleterious consequences of granulocyte transfusions in patients with pulmonary aspergillosis may have had some contribution to their worse outcome. 41 Previous murine and rabbit models of disseminated and pulmonary aspergillosis demonstrated that A. terreus was resistant to amphotericin B, whereas antifungal therapy with triazoles, such as itraconazole and posaconazole, was more active.
3,31
Therefore, our study clearly describes the apparent refractoriness of A. terreus to polyene therapy and its association with a poor outcome reported in previous clinical studies. 20 Forty-nine percent of patients with A. terreus received a lipid amphotericin B-containing regimen as part of their primary antifungal therapy and 42% as salvage antifungal therapy, but only 21% of patients with A. terreus had a favourable outcome. In our study, patients who used a lipid amphotericin B-containing regimen either in primary or salvage therapy had a worse outcome when compared with those who used an azole-containing regimen, regardless of the species. In addition, by multivariate analysis, treatment with azoles was associated with an improved response and had a protective effect against IA-associated mortality independently of species. These findings were consistent with the study by Steinbach et al. 20 Multivariate analysis of data on 83 patients with A. terreus showed that overall survival was greater for patients who received voriconazole as a part of their antifungal regimen than for patients who received other systemic antifungal therapies, such as amphotericin B-containing regimens. In reviews by Iwen et al., 11, 12 it was found that, for all Aspergillus species isolated, A. terreus was associated with the greatest mortality and had the greatest percentage of cases of IA not diagnosed until post-mortem examination. Similarly, other studies (which included our patients) showed that infections caused by A. terreus had a poor response and higher mortality at 6 or 12 weeks when compared with infections with other Aspergillus species. 18, 20 Although the use of an amphotericin B-containing regimen may account, in part, for the higher mortality seen in the A. terreus group, our current study offers unique insight into the potential for A. terreus infection as a marker for treatment failure and death irrespective of the antifungal regimen used.
Our study has the limitation of being retrospective, evaluating clinical notes, radiological and laboratory data, but its importance relies on its description of a high number of cases over a prolonged period of time. Furthermore, the complexity of the IA and the large number of variables affecting outcome could have limited the ability of this study to control for all patient and confounding variables. Another limitation is that a galactomannan assay was not included among the diagnostic tools because it was not available at the start of our study. However, it is now commonly used and it is helpful in the diagnosis and categorization of IA.
In conclusion, despite these limitations, meaningful observations were made in this study. The epidemiology of IA is changing with the increasing incidence of A. terreus in patients with HMs. Infection due to A. terreus is associated with a poor clinical outcome and higher mortality irrespective of the type of antifungal therapy used. Improved methods for the timely isolation and identification of A. terreus are clearly needed and are extremely Aspergillus terreus versus Aspergillus non-terreus important from both therapeutic and prognostic standpoints. The growing ascertainment of amphotericin B resistance of A. terreus infection affirms the empirical use of new-generation azoles such as voriconazole or posaconazole in HM patients with evidence of IA, especially IA due to emerging A. terreus.
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